NPPB and heart failure: Subgroup analysis revealed significant improvements in LAD, LVESD, LVEDD, LVEF, NT-proBNP levels, and MLHFQ scores among patients with VHD heart failure after 1 month of treatment with Vericiguat combined with the “new quadruple” drugs compared to pre-treatment values (p < 0.01).